Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Placebo-Controlled Double-Blind Randomized Parallel Groups Study to Determine the Efficacy and Safety of S1B-509 for Weight Loss

NCT06517797 is registered in ClinicalTrials.gov with S1 Biopharma, Inc. as lead sponsor.

NCT NCT06517797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06517797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Placebo-Controlled Double-Blind Randomized Parallel Groups Study to Determine the Efficacy and Safety of S1B-509 for Weight Loss
Lead sponsor
S1 Biopharma, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 15, 2025
Completion date
December 15, 2027
Enrollment
210 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

obesity